|
NCT03814447
|
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
|
Not yet recruiting
|
Drug: anti- MESO CAR-T cells; Drug: Fludarabine; Drug: Cyclophosphamide
|
Early Phase 1
|
10
|
2019-04-01
|
China
|
|
NCT03747965
|
Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors
|
Recruiting
|
Biological: Mesothelin-directed CAR-T cells
|
Phase 1
|
10
|
2018-11-01
|
China
|
|
NCT03608618
|
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
|
Recruiting
|
Biological: MCY-M11
|
Phase 1
|
15
|
2018-08-27
|
United States
|
|
NCT03615313
|
PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor
|
Recruiting
|
Biological: PD-1 antibody expressing mesoCAR-T cells
|
Phase 1/2
|
50
|
2018-08-06
|
China
|
|
NCT03638193
|
Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
|
Recruiting
|
Biological: CART-meso cells
|
Not Applicable
|
10
|
2018-07-11
|
China
|
|
NCT03545815
|
Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.
|
Recruiting
|
Biological: anti-mesothelin CAR-T cells
|
Phase 1
|
10
|
2018-03-01
|
China
|
|
NCT03356808
|
Antigen-specific T Cells Against Lung Cancer
|
Recruiting
|
Biological: Lung cancer-specific T cells
|
Phase 1/2
|
20
|
2017-12-15
|
China
|
|
NCT03356795
|
Intervention of CAR-T Against Cervical Cancer
|
Recruiting
|
Biological: Cervical cancer-specific CAR-T cells
|
Phase 1/2
|
20
|
2017-11-15
|
China
|
|
NCT03497819
|
Autologous CARTmeso/19 Against Pancreatic Cancer
|
Active, not recruiting
|
Biological: CARTmeso CART19
|
Early Phase 1
|
10
|
2017-10-01
|
China
|
|
NCT03323944
|
CAR T Cell Immunotherapy for Pancreatic Cancer
|
Recruiting
|
Biological: huCART-meso cells
|
Phase 1
|
18
|
2017-09-15
|
United States
|
|
NCT03198052
|
HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
|
Recruiting
|
Biological: CAR-T cells targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, or CD80/86
|
Phase 1
|
30
|
2017-07-01
|
China
|
|
NCT03267173
|
Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
|
Recruiting
|
Drug: Chimeric antigen receptor T cell
|
Early Phase 1
|
10
|
2017-06-15
|
China
|
|
NCT03182803
|
CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor
|
Recruiting
|
Biological: CTLA-4/PD-1 antibodies expressing mesoCAR-T
|
Phase 1/2
|
40
|
2017-06-07
|
China
|
|
NCT03054298
|
CAR T Cells in Mesothelin Expressing Cancers
|
Recruiting
|
Biological: huCART-meso cells
|
Phase 1
|
30
|
2017-03-01
|
United States
|
|
NCT03030001
|
PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies
|
Unknown status
|
Biological: PD-1 antibody expressing mesothelin specific CAR-T cells
|
Phase 1/2
|
40
|
2017-02-15
|
China
|
|
NCT02930993
|
Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors
|
Recruiting
|
Biological: anti-mesothelin CAR T cells
|
Phase 1
|
20
|
2016-08-01
|
China
|
|
NCT02959151
|
A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
|
Unknown status
|
Drug: CAR-T cell
|
Phase 1/2
|
20
|
2016-07-01
|
China
|
|
NCT02792114
|
T-Cell Therapy for Advanced Breast Cancer
|
Recruiting
|
Drug: Cyclophosphamide; Biological: Mesothelin-targeted T cells; Drug: AP1903
|
Phase 1
|
36
|
2016-06-01
|
United States
|
|
NCT02706782
|
A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma
|
Unknown status
|
Drug: TAI-meso-CART
|
Phase 1
|
30
|
2016-03-01
|
China
|
|
NCT02580747
|
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
|
Unknown status
|
Biological: anti-meso-CAR vector transduced T cells
|
Phase 1
|
20
|
2015-10-01
|
China
|
|
NCT02414269
|
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
|
Recruiting
|
Genetic: iCasp9M28z T cell infusions; Drug: cyclophosphamide
|
Phase 1
|
48
|
2015-05-01
|
United States
|
|
NCT02465983
|
Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
|
Completed
|
Biological: CART-meso-19 T cells; Drug: Cyclophosphamide
|
Phase 1
|
4
|
2015-05-01
|
United States
|
|
NCT02388828
|
CART-meso Long-term Follow-up
|
Active, not recruiting
|
Biological: lentiviral-based CART meso therapy
| |
10
|
2015-03-01
|
United States
|
|
NCT02159716
|
CART-meso in Mesothelin Expressing Cancers
|
Completed
|
Biological: CART-meso
|
Phase 1
|
19
|
2014-06-01
|
United States
|
|
NCT01897415
|
Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer
|
Completed
|
Biological: Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
|
Phase 1
|
16
|
2013-07-01
|
United States
|
|
NCT01583686
|
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
|
Terminated
|
Drug: Fludarabine; Biological: Anti-mesothelin CAR transduced PBL; Drug: Cycolphosphamide; Drug: Aldesleukin
|
Phase 1/2
|
15
|
2012-05-04
|
United States
|
|
NCT01355965
|
Autologous Redirected RNA Meso-CIR T Cells
|
Completed
|
Biological: Autologous T cells
|
Phase 1
|
18
|
2011-03-01
|
United States
|
